$6m Placement to Accelerate IDTs Generic Drug Portfolio
Filed with ASX · · 2 pages · English
Earlier from IDT Australia
Later from IDT Australia
- Thiotepa - Contract Extension and Revenues
- Manufacturing partner appointed
- Reinstatement to Official Quotation
- FDA Approval for Temozolomide
- CMAX - Opening of new Clinical Trial Facility
Follow IDT Australia into a list and get an email when it puts out news.
Follow IDT Australia